These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 32584703)

  • 1. Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis: A Clinical Review.
    Gong Z; Wang Y
    JCO Oncol Pract; 2020 Aug; 16(8):453-461. PubMed ID: 32584703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitor-induced diarrhea and colitis: an overview.
    Zoghbi M; Burk KJ; Haroun E; Saade M; Carreras MTC
    Support Care Cancer; 2024 Sep; 32(10):680. PubMed ID: 39311981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study.
    Sleiman J; Wei W; Shah R; Faisal MS; Philpott J; Funchain P
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34158318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review.
    Nakane T; Mitsuyama K; Yamauchi R; Kakuma T; Torimura T
    Kurume Med J; 2023 Jul; 68(2):43-52. PubMed ID: 37100606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis.
    Abu-Sbeih H; Herrera LN; Tang T; Altan M; Chaftari AP; Okhuysen PC; Jenq RR; Wang Y
    J Immunother Cancer; 2019 Sep; 7(1):242. PubMed ID: 31488205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-checkpoint inhibitors induced diarrhea and colitis: a review of incidence, pathogenesis and management.
    Abu-Sbeih H; Ali FS; Wang Y
    Curr Opin Gastroenterol; 2020 Jan; 36(1):25-32. PubMed ID: 31609734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study.
    Abu-Sbeih H; Ali FS; Alsaadi D; Jennings J; Luo W; Gong Z; Richards DM; Charabaty A; Wang Y
    J Immunother Cancer; 2018 Dec; 6(1):142. PubMed ID: 30518410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of Immune Checkpoint Inhibitor-related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections.
    Ma W; Gong Z; Abu-Sbeih H; Peng Y; Peng F; Zou F; Charabaty A; Okhuysen PC; McQuade JL; Altan M; Zhang HC; Thomas AS; Wang Y
    Am J Clin Oncol; 2021 Aug; 44(8):402-408. PubMed ID: 34107499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis.
    Zou F; Wang X; Glitza Oliva IC; McQuade JL; Wang J; Zhang HC; Thompson JA; Thomas AS; Wang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mirroring UC care pathways in refractory immune checkpoint inhibitor (ICI)-mediated colitis: distinct features and common pathways.
    Sleiman J; Brand RM; Pai R; Brand RE; Rhee J; Schwartz M; Davar D
    Clin J Gastroenterol; 2023 Oct; 16(5):680-684. PubMed ID: 37452993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis.
    Mooradian MJ; Wang DY; Coromilas A; Lumish M; Chen T; Giobbie-Hurder A; Johnson DB; Sullivan RJ; Dougan M
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study.
    Zou F; Faleck D; Thomas A; Harris J; Satish D; Wang X; Charabaty A; Ernstoff MS; Glitza Oliva IC; Hanauer S; McQuade J; Obeid M; Shah A; Richards DM; Sharon E; Wolchok J; Thompson J; Wang Y
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34789551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal Tract Adverse Events.
    Abu-Sbeih H; Wang Y
    Adv Exp Med Biol; 2020; 1244():247-253. PubMed ID: 32301019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitor-associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies.
    Tran AN; Wang M; Hundt M; Chugh R; Ohm J; Grimshaw A; Ciarleglio M; Hung KW; Proctor DD; Price CC; Laine L; Al-Bawardy B
    J Immunother; 2021 Oct; 44(8):325-334. PubMed ID: 34380976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoint Inhibitors-Induced Colitis.
    Tian Y; Abu-Sbeih H; Wang Y
    Adv Exp Med Biol; 2018; 995():151-157. PubMed ID: 30539510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesalamine and cholestyramine for immune checkpoint inhibitor-mediated diarrhea and colitis.
    Hollander B; Khurana S; Jacob JS; Altan M; Wang J; Zhao D; Varatharajalu K; Alasadi M; Thomas AS; Wang Y
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3637-3648. PubMed ID: 35972690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint Inhibitor-Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis.
    Nielsen DL; Juhl CB; Chen IM; Kellermann L; Nielsen OH
    Cancer Treat Rev; 2022 Sep; 109():102440. PubMed ID: 35917654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer.
    Liu C; Shatila M; Mathew A; Machado AP; Thomas A; Zhang HC; Thomas AS; Faleck D; Funchain P; Philpott J; Grivas P; Obeid M; Carbonnel F; Wang Y
    J Cancer; 2023; 14(10):1913-1919. PubMed ID: 37476185
    [No Abstract]   [Full Text] [Related]  

  • 19. Implementing an immunotherapy toxicity (IOTOX) GI service improves outcomes in patients with immune-mediated diarrhea and colitis.
    Saji A; Chopra M; Jacob J; Altan M; Alhalabi O; Shah AY; Qiao W; Wang Y; Thomas A
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):5841-5852. PubMed ID: 36585982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting.
    Bonanno L; Lorenzi M; Massa D; De Nuzzo M; Angerilli V; Zingone F; Barberio B; Russi A; Girardi F; Ferro A; Dal Maso A; Frega S; Pasello G; Dei Tos AP; Coppola M; Fassan M; Savarino EV; Guarneri V
    Oncologist; 2024 Jan; 29(1):e118-e130. PubMed ID: 37603442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.